Cadrenal holders approve equity plan boost to 1,000,000 shares and 960,000-share warrant issuance

Cadrenal Therapeutics, Inc.

Stockholders approved Amendment No. 2 to the 2022 Successor Equity Incentive Plan, raising the share reserve by 323,542 shares to 1,000,000 shares; the ISO limit was also raised to 1,000,000.
Quang X. Pham was elected Class I director with 1,039,666 votes for and 14,342 withheld, to serve until the 2029 annual meeting.
Holders approved issuance of up to 960,000 shares of common stock upon exercise of Series C-1 warrants issued in the private placement that closed July 1, 2026, per Nasdaq Rule 5635(d).
WithumSmith+Brown, P.C. ratified as independent auditor for the fiscal year ending December 31, 2026 (2,110,693 for, 39,121 against, 5,527 abstentions).
Record date July 27, 2026: 3,567,592 shares outstanding, with 2,155,341 shares represented (quorum) at the September 24, 2026 meeting; the adjournment proposal passed but was not needed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.